Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2001-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/13543784.10.6.1075PMID 11772236
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tissue inhibitor of metalloproteinase‐4 instigates apoptosis in transformed cardiac fibroblasts

  2001cited by this paper
• Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.

  2001cited by this paper
• Association of trypsin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma

  2001cited by this paper
• Epilysin, a Novel Human Matrix Metalloproteinase (MMP-28) Expressed in Testis and Keratinocytes and in Response to Injury*

  2001cited by this paper
• Matrix Metalloproteinases in Multiple Myeloma

  2000cited by this paper
• Localization of the Death Domain of Tissue Inhibitor of Metalloproteinase-3 to the N Terminus

  2000cited by this paper
• Tissue inhibitors of metalloproteinases: evolution, structure and function.

  2000cited by this paper
• Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.

  2000cited by this paper
• Ongoing trials with matrix metalloproteinase inhibitors

  2000influential reference
• Tissue Inhibitor of Metalloproteinase‐2 Induces Apoptosis in Human T Lymphocytes

  1999cited by this paper
• Preventive Effect of Matrix Metalloproteinase Inhibitor, R‐94138, in Combination with Mitomycin C or Cisplatin on Peritoneal Dissemination of Human Gastric Cancer Cell Line TMK‐1 in Nude Mice

  1999cited by this paper
• Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer

  1999cited by this paper
• Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein

  1999cited by this paper
• Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials

  1999cited by this paper
• Marimastat in patients with advanced pancreatic cancer: a dose-finding study.

  1999cited by this paper
• Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.

  1999cited by this paper
• The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis.

  1999cited by this paper
• Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.

  1999cited by this paper
• Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma.

  1999cited by this paper
• Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells.

  1999cited by this paper
• Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation.

  1999cited by this paper
• Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage

  1999cited by this paper
• Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors.

  1999cited by this paper
• Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation-induced apoptosis of brain tumor cells

  1998cited by this paper
• Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase.

  1998cited by this paper
• p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs

  1998cited by this paper
• Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells.

  1998cited by this paper
• Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis

  1998cited by this paper
• Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis.

  1998cited by this paper
• Fas ligand expression in nodal non-Hodgkin's lymphoma.

  1998cited by this paper
• In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.

  1998cited by this paper
• Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells.

  1998cited by this paper
• Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity

  1998cited by this paper
• Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.

  1998cited by this paper
• Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.

  1998cited by this paper
• Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.

  1998cited by this paper
• Fas‐mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage

  1998cited by this paper
• Downregulation of Fas ligand by shedding

  1998influential reference
• The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.

  1998cited by this paper
• A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells

  1997cited by this paper
• Structural features and biochemical properties of TNF-alpha converting enzyme (TACE).

  1997cited by this paper
• Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)*

  1997cited by this paper
• Activation mechanisms of matrix metalloproteinases.

  1997cited by this paper
• Coordinated expression of matrilysin during TPA-induced apoptosis of LNCaP cells: two parallel processes affected by TPA.

  1997cited by this paper
• Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.

  1997cited by this paper
• Constitutive expression of Fas ligand in large granular lymphocyte leukaemia

  1997cited by this paper
• A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.

  1997cited by this paper
• The matrix metalloproteinases and their inhibitors in pancreatic cancer

  1997cited by this paper
• Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α

  1997cited by this paper
• Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

  1997cited by this paper
• Human lung carcinomas express Fas ligand.

  1997cited by this paper
• Development of Inflammatory Angiogenesis by Local Stimulation of Fas In Vivo

  1997cited by this paper
• TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells.

  1997cited by this paper
• Changing views of the role of matrix metalloproteinases in metastasis.

  1997influential reference
• Expression of Fas ligand in liver metastases of human colonic adenocarcinomas.

  1997cited by this paper
• Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival.

  1996cited by this paper
• An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand

  1996cited by this paper
• Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?

  1996cited by this paper
• Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

  1996cited by this paper
• Regulation of matrilysin in the rat uterus.

  1996cited by this paper
• The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

  1996cited by this paper
• Fas ligand in human serum

  1996cited by this paper
• Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well.

  1996cited by this paper
• FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis (*)

  1996cited by this paper
• Regulation of matrilysin in the rat uterus

  1996cited by this paper
• Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

  1996cited by this paper
• FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex.

  1996cited by this paper
• Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate.

  1995cited by this paper
• A role for CD95 ligand in preventing graft rejection

  1995cited by this paper
• Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation

  1995cited by this paper
• Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas

  1995cited by this paper
• FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis.

  1995cited by this paper
• Metalloproteinase-mediated release of human Fas ligand

  1995cited by this paper
• Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

  1995cited by this paper
• Expression of the functional soluble form of human fas ligand in activated lymphocytes.

  1995cited by this paper
• Molecular insights into cancer invasion: strategies for prevention and intervention.

  1995cited by this paper
• Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen.

  1995cited by this paper
• Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity.

  1994cited by this paper
• Purification and characterization of the Fas-ligand that induces apoptosis

  1994cited by this paper
• Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo.

  1994cited by this paper
• Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth

  1994cited by this paper
• Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

  1993cited by this paper
• Induction of metalloproteinase activity in human T-lymphocytes.

  1993cited by this paper
• The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen.

  1992cited by this paper
• Expression and localization of the matrix metalloproteinase pump‐1 (MMP‐7) in human gastric and colon carcinomas

  1991cited by this paper
• The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.

  1991cited by this paper
• Alpha 2-macroglobulin and tissue inhibitor of metalloproteinases: collagenase inhibitors in human preovulatory ovaries.

  1990cited by this paper
• Monoclonal antibody-mediated tumor regression by induction of apoptosis.

  1989cited by this paper

• Novel aminoanilide compounds as MMP-2/MMP-9 inhibitors: Design, synthesis, biological evaluation, and molecular modeling studies

  2026cites this paper
• Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review

  2022cites this paper
• MMP-7 marks severe pancreatic cancer and alters tumor cell signaling by proteolytic release of ectodomains.

  2022cites this paper
• Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review.

  2019cites this paper
• The interplay between MDM2 and PSMA in metastatic breast cancer cells

  2016cites this paper
• Batimastat Nanoparticles Associated with Transcatheter Arterial Chemoembolization Decrease Hepatocellular Carcinoma Recurrence

  2014cites this paper
• Gemcitabine sensitizes lung cancer cells to Fas/FasL system‐mediated killing

  2014cites this paper
• A Novel MMP-2 Inhibitor 3-azidowithaferin A (3-azidoWA) Abrogates Cancer Cell Invasion and Angiogenesis by Modulating Extracellular Par-4

  2012cites this paper
• A motogén szignál vizsgálata humán melanómasejtekben

  2011cites this paper
• Prognostic and biological implications of epigenetic changes in leukemia

  2011cites this paper
• Different apoptosis modalities in periprosthetic membranes.

  2010cites this paper
• Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenviroment

  2008cites this paper
• Increased glomerular matrix metalloproteinase activity in murine lupus nephritis.

  2008cites this paper
• MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line

  2007cites this paper
• Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?

  2006cites this paper
• Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma.

  2006influential citation
• Signal transduction pathways implicated in neural recognition molecule L1 triggered neuroprotection and neuritogenesis

  2005cites this paper
• Matrix metalloproteinases as therapeutic targets in cancer.

  2005cites this paper
• Multiple roles of matrix metalloproteinases during apoptosis

  2005cites this paper
• Disfunction of the Apoptotic Pathway in Cancer Cells

  2005cites this paper
• Fas Ligand-Mediated Apoptosis in Degenerative Disorders of the Brain

  2004cites this paper
• Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.

  2004cites this paper
• New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.

  2004cites this paper
• CD147 and matrix metalloproteinase‐2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma

  2004cites this paper
• Fas Ligand-Mediated Apoptosis in Degenerative Disorders of the Brain

  2003cites this paper
• Apoptotic cues from the extracellular matrix: regulators of angiogenesis

  2003cites this paper
• Shedding of Fas ectodomain that affects apoptosis of hepatocytes occurring in regenerative liver

  2002cites this paper